新型苯并噻唑衍生物的合成、荧光性质及SHP2生物活性探究
Novel Benzothiazole Derivatives: Synthesis, Fluorescence Properties, Bioactivity for SHP2
DOI: 10.12677/hjmce.2026.142010, PDF,   
作者: 朱隽威, 闫 薛, 王文龙*：江南大学生命科学与健康工程学院，江苏 无锡；高立信：中国科学院上海药物研究所，国家新药筛选中心，上海
关键词: 苯并噻唑；水杨酸；SHP2；光学性质；选择性；Benzothiazole； Salicylic Acid； SHP2； Optical Properties； Selectivity
摘要: 本文设计并合成了一系列含水杨酸片段的新型苯并噻唑衍生物。然后对它们的光学性质和生物活性进行了评价。其中，化合物Y5和Y7表现出了明显的抑制活性，对SHP2的IC50分别为32.3 ± 2.0 µM和3.46 ± 0.06 µM，化合物Y7对其它PTPs表现出了良好的选择性。此外，化合物Y7还表现出了优异的荧光性质。该研究为开发具有荧光特性和生物活性的SHP2分子提供了一条潜在的途径。
Abstract: In this study, we designed and synthesized a series of novel benzothiazole-salicylic acid derivatives, then their optical properties and biological activities were evaluated. Among them, compound Y5 and Y7 showed obvious inhibitory activities against SHP2, which were 32.3 ± 2.0 µM and 3.46 ± 0.06 µM, respectively. Compound Y7 showed good selectivity against other PTPs. In addition, compound Y7 exhibited excellent fluorescence properties. This study provided a potential pathway for the development of SHP2 molecules with fluorescence properties and biological activity.
文章引用：朱隽威, 闫薛, 高立信, 王文龙. 新型苯并噻唑衍生物的合成、荧光性质及SHP2生物活性探究[J]. 药物化学, 2026, 14(2): 97-106. https://doi.org/10.12677/hjmce.2026.142010

参考文献

[1] Tonks, N.K. (2013) Protein Tyrosine Phosphatases—From Housekeeping Enzymes to Master Regulators of Signal Transduction. The FEBS Journal, 280, 346-378. [Google Scholar] [CrossRef] [PubMed]
[2] Lee, H., Yi, J., Lawan, A., Min, K. and Bennett, A.M. (2015) Mining the Function of Protein Tyrosine Phosphatases in Health and Disease. Seminars in Cell & Developmental Biology, 37, 66-72. [Google Scholar] [CrossRef] [PubMed]
[3] Hendriks, W.J.A.J., Elson, A., Harroch, S., Pulido, R., Stoker, A. and den Hertog, J. (2012) Protein Tyrosine Phosphatases in Health and Disease. The FEBS Journal, 280, 708-730. [Google Scholar] [CrossRef] [PubMed]
[4] Chan, R.J. and Feng, G. (2006) PTPN11 Is the First Identified Proto-Oncogene That Encodes a Tyrosine Phosphatase. Blood, 109, 862-867. [Google Scholar] [CrossRef] [PubMed]
[5] Asmamaw, M.D., Shi, X., Zhang, L. and Liu, H. (2022) A Comprehensive Review of SHP2 and Its Role in Cancer. Cellular Oncology, 45, 729-753. [Google Scholar] [CrossRef] [PubMed]
[6] Sodir, N.M., Pathria, G., Adamkewicz, J.I., Kelley, E.H., Sudhamsu, J., Merchant, M., et al. (2023) SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment. Cancer Discovery, 13, 2339-2355. [Google Scholar] [CrossRef] [PubMed]
[7] Yang, W., Klaman, L.D., Chen, B., Araki, T., Harada, H., Thomas, S.M., et al. (2006) An Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival. Developmental Cell, 10, 317-327. [Google Scholar] [CrossRef] [PubMed]
[8] Chen, D., Barsoumian, H.B., Yang, L., Younes, A.I., Verma, V., Hu, Y., et al. (2020) SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer. Cancer Immunology Research, 8, 883-894. [Google Scholar] [CrossRef] [PubMed]
[9] Christofides, A., Katopodi, X., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., et al. (2022) SHP-2 and PD-1-SHP-2 Signaling Regulate Myeloid Cell Differentiation and Antitumor Responses. Nature Immunology, 24, 55-68. [Google Scholar] [CrossRef] [PubMed]
[10] Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D.L., van der Burgt, I., et al. (2002) PTPN11 Mutations in Noonan Syndrome: Molecular Spectrum, Genotype-Phenotype Correlation, and Phenotypic Heterogeneity. The American Journal of Human Genetics, 70, 1555-1563. [Google Scholar] [CrossRef] [PubMed]
[11] Loh, M.L., et al. (2004) Mutations in PTPN11 Implicate the SHP-2 Phosphatase in Leukemogenesis. Blood, 103, 2325-2331. [Google Scholar] [CrossRef] [PubMed]
[12] Miyamoto, D., Miyamoto, M., Takahashi, A., Yomogita, Y., Higashi, H., Kondo, S., et al. (2008) Isolation of a Distinct Class of Gain-of-Function SHP-2 Mutants with Oncogenic RAS-Like Transforming Activity from Solid Tumors. Oncogene, 27, 3508-3515. [Google Scholar] [CrossRef] [PubMed]
[13] Adhikari, D.P., Biener, G., Stoneman, M.R., Badu, D.N., Paprocki, J.D., Eis, A., et al. (2021) Comparative Photophysical Properties of Some Widely Used Fluorescent Proteins under Two-Photon Excitation Conditions. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 262, Article ID: 120133. [Google Scholar] [CrossRef] [PubMed]
[14] Dai, Z.R., Ge, G.B., Feng, L., Ning, J., Hu, L., Jin, Q., et al. (2015) A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1a. Journal of the American Chemical Society, 137, 14488-14495. [Google Scholar] [CrossRef] [PubMed]
[15] Yan, X., Zhang, C., Gao, L., Liu, M., Yang, Y., Yu, L., et al. (2024) Novel Imidazo[1,2,4] Triazole Derivatives: Synthesis, Fluorescence, Bioactivity for SHP1. European Journal of Medicinal Chemistry, 265, Article ID: 116027. [Google Scholar] [CrossRef] [PubMed]
[16] Wang, W., Chen, X., Gao, Y., Gao, L., Sheng, L., Zhu, J., et al. (2017) Benzo[c][1,2,5]thiadiazole Derivatives: A New Class of Potent Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) Inhibitors. Bioorganic & Medicinal Chemistry Letters, 27, 5154-5157. [Google Scholar] [CrossRef] [PubMed]
[17] Gobert, R.P., van den Eijnden, M., Szyndralewiez, C., Jorand-Lebrun, C., Swinnen, D., Chen, L., et al. (2009) GLEPP1/Protein-Tyrosine Phosphatase Φ Inhibitors Block Chemotaxis in Vitro and in Vivo and Improve Murine Ulcerative Colitis. Journal of Biological Chemistry, 284, 11385-11395. [Google Scholar] [CrossRef] [PubMed]
[18] He, Y., Liu, S., Menon, A., Stanford, S., Oppong, E., Gunawan, A.M., et al. (2013) A Potent and Selective Small-Molecule Inhibitor for the Lymphoid-Specific Tyrosine Phosphatase (LYP), a Target Associated with Autoimmune Diseases. Journal of Medicinal Chemistry, 56, 4990-5008. [Google Scholar] [CrossRef] [PubMed]